Irgass (Bromfenac)

Bromfenac works by inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes in ocular tissues, which blocks the formation of prostaglandins. Lower prostaglandin levels reduce inflammation, vascular permeability, and pain signaling within the eye.

The specific dosing regimen for Irgass is determined by the prescribing eye care professional based on the patient’s condition and response. Typically, a single drop is instilled in the affected eye as directed, but the exact frequency and duration are set by the clinician.

Safety data for bromfenac ophthalmic solution in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and clinicians usually advise caution or alternative therapy.

To order Irgass, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irgass (bromfenac) is similar to other ophthalmic NSAIDs such as nepafenac, offering potent anti‑inflammatory and analgesic effects with once‑daily dosing in many cases. Compared with steroid eye drops, bromfenac carries a lower risk of raising intraocular pressure but may be less effective for severe uveitis.

Irgass should be stored at room temperature, ideally below 25 °C, in its original container. Protect the solution from direct light and moisture, and keep the cap tightly closed when not in use to maintain sterility.

Irgass is administered as an ophthalmic solution. The patient instills the prescribed number of drops into the affected eye(s) using the provided dropper, typically avoiding contact between the tip and the eye or any surface to maintain sterility.

Serious risks, although rare, include corneal ulceration, a significant increase in intraocular pressure, severe allergic reactions such as angioedema, and potential vision loss. Patients should report any sudden worsening of vision, intense eye pain, or signs of infection promptly.

Irgass should not be used by individuals with a known hypersensitivity to bromfenac, other NSAIDs, or any component of the formulation. It is also contraindicated in patients with active ocular infections that could be aggravated by NSAID therapy.